Holger H.
- Country
- Germany
- Department
- Internal Medicine
Research Overview
- A Randomized, Open-label, Phase 3 Study of Acalabrutinib in Combination with Rituximab and Reduced Dose CHOP (R-miniCHOP) in Older Adults with Untreated Diffuse Large B-Cell Lymphoma (ARCHED/GLA 2022-1)
- A Phase 2/3, Multicenter, Randomized, Dose Optimization (Part I), Double-blind (Part II) Study to Compare the Efficacy and Safety of Oral Azacitidine (Oral-Aza, ONUREG®) plus Best Supportive Care (BSC) versus Placebo plus BSC in Participants with IPSS-R Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)
- Efficacy and Safety Comparison of Obinutuzumab-Venetoclax vs. Obinutuzumab-Chlorambucil in Untreated CLL with Comorbidities
Data & Insights
Has run more than one trial at 378 of 643 partner sites.
Specializations
Hematologic Malignancies – B‑cell Lymphomas
The investigator concentrates on aggressive and indolent B‑cell lymphomas, emphasizing therapeutic strategies that improve remission depth and durability.
- Diffuse large B‑cell lymphoma
- Follicular lymphoma
- Marginal zone lymphoma
- Mantle cell lymphoma
- High‑grade B‑cell lymphoma
Efforts target novel combinations and biomarkers to refine risk‑adapted treatment.
Chronic Lymphocytic Leukemia and Related Disorders
Focused on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), the investigator explores regimens that address high‑risk genetic features.
- TP53‑mutated CLL
- Unmutated IGHV CLL
- Relapsed/refractory CLL
- Co‑existing medical conditions in CLL
- Venetoclax‑based combinations
Therapeutic aims include fixed‑duration approaches and MRD‑guided strategies.
Multiple Myeloma and Waldenström’s Macroglobulinemia
In the realm of plasma‑cell disorders, the investigator evaluates innovative agent combinations for multiple myeloma and Waldenström’s macroglobulinemia (WM).
- Newly diagnosed multiple myeloma
- Relapsed/refractory multiple myeloma
- Treatment‑naïve WM
- BTK‑inhibitor‑based regimens
- MRD‑negative response assessment
Key interest lies in enhancing progression‑free survival while minimizing toxicity.
Myeloproliferative Neoplasms
The investigator’s work includes targeted therapy for disorders such as polycythemia vera and myelofibrosis, particularly after JAK‑inhibitor failure.
- Hydroxyurea resistance in polycythemia vera
- JAK‑inhibitor‑refractory myelofibrosis
- TP53‑wild‑type myelofibrosis
- Combination JAK‑inhibitor therapies
- Spleen volume reduction endpoints
Research aims to extend disease control and improve symptom burden.
Myelodysplastic Syndromes, Acute Myeloid Leukemia and Selected Solid Tumors
Beyond hematology, the investigator addresses high‑risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and solid‑tumor entities such as colorectal cancer and hormone‑receptor‑positive HER2‑negative breast cancer.
- Low‑risk MDS anemia management
- Intermediate‑ or adverse‑risk AML
- MRD‑guided AML therapy
- Adjuvant therapy in stage II colon cancer
- Peri‑operative treatment for HER2‑negative breast cancer
Efforts focus on personalized treatment intensification and biomarker‑driven decision making.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.